LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Harbour BioMed brings advanced antibody discovery platforms to the table
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Subscribe To Our Newsletter & Stay Updated
